The effect of HCV serological status on Doxorubicin based chemotherapy induced toxicity and disease-free survival in breast cancer patients
KY Welaya, S El-Assal, OE Salama… - Alexandria Journal of …, 2015 - ajol.info
Background: Breast cancer and HCV are two frequent diseases in Egypt. There is a
considerable probability of concurrent affection. This concurrence creates a subpopulation,
which needs special evaluation and care. Objective: To evaluate a subset of Egyptian breast
cancer patients receiving Doxorubicin based adjuvant chemotherapy, with HCV
seropositivity (group 2) compared to HCV seronegative patients (group 1). Methods: 102
breast cancer patients, planned to receive Doxorubicin based adjuvant chemotherapy, at the …
considerable probability of concurrent affection. This concurrence creates a subpopulation,
which needs special evaluation and care. Objective: To evaluate a subset of Egyptian breast
cancer patients receiving Doxorubicin based adjuvant chemotherapy, with HCV
seropositivity (group 2) compared to HCV seronegative patients (group 1). Methods: 102
breast cancer patients, planned to receive Doxorubicin based adjuvant chemotherapy, at the …
The effect of HCV serological status on doxorubicin-based chemotherapy-induced toxicity and disease-free survival in breast cancer patients.
SE Abd-El-Moneim, KY Welaya, S El-Assal, OE Salama… - 2013 - ascopubs.org
1075 Background: Breast cancer and HCV are two frequent diseases in Egypt. There is a
considerable probability of concurrent affection. This concurrence creates a subpopulation
which needs special evaluation and care. Methods: To evaluate a subset of Egyptian breast
cancer patients receiving doxorubicin based adjuvant chemotherapy, with HCV
seropositivity (Group 2) compared to HCV seronegative patients (Group 1). 102 breast
cancer patients, planned to receive Doxorubicin based adjuvant chemotherapy, at the …
considerable probability of concurrent affection. This concurrence creates a subpopulation
which needs special evaluation and care. Methods: To evaluate a subset of Egyptian breast
cancer patients receiving doxorubicin based adjuvant chemotherapy, with HCV
seropositivity (Group 2) compared to HCV seronegative patients (Group 1). 102 breast
cancer patients, planned to receive Doxorubicin based adjuvant chemotherapy, at the …
以上显示的是最相近的搜索结果。 查看全部搜索结果